alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 32**

 

**CERTIFICATION**

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350, as adopted), Pedro Lichtinger, the Chief Executive Officer of Optimer Pharmaceuticals, Inc. (the “Company”), and John D. Prunty, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

 

1.              The Company’s Annual Report on Form 10-K for the year ended December 31, 2010, to which this Certification is attached as Exhibit 32 (the “Annual Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.              The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Annual Report and results of operations of the Company for the period covered by the Annual Report.

 
| Dated:   March 10, 2011  |   |                                         |
|-------------------------------|--------|----------------------------------------------|
|                          |   |                                         |
| /s/ Pedro Lichtinger          |   | /s/ John D. Prunty                           |
| Pedro Lichtinger              |   | John D. Prunty                               |
| Chief Executive Officer       |   | Chief Financial Officer                      |
| (Principal Executive Officer) |   | (Principal Financial and Accounting Officer) |

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

 

----
#### § 3109.13 Notice.

After the BLM has determined that a lease of a right-of-way or any portion thereof is consistent with the public interest, either upon consideration of an application for lease or on its own motion, the authorized officer will serve notice on the owner or lessee of the oil and gas rights of the adjoining lands. The adjoining landowner or lessee will be allowed a reasonable time, as provided in the notice, within which to submit a bid for the percent of compensatory royalty, the owner or lessee must pay for the extraction of the oil and gas underlying the right-of-way through wells on such adjoining lands. The owner of the right-of-way will be given the same time period to submit a bid for the lease.
Exhibit 31.2

SECTION 302 CERTIFICATION I, Alan Bowen , certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Innovate Oncology,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report; 3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
exchange act rules 13a-14 and 15d-14 for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal control
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls.

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of my most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



                            Date: August 22, 2005

                            By: /s/ Alan Bowen
                            ------------------------------------
                            Alan Bowen
                            CFO, Secretary, Treasurer & Director
                            (Principal Financial Officer)

                                       20
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsWorkload-Matched Adaptive Automation Support of Air Traffic Controller Information Processing StagesAdaptive automation (AA) has been explored as a solution to the problems associated with human-automation interaction in supervisory control environments. However, research has focused on the performance effects of dynamic control allocations of early stage sensory and information acquisition functions. The present research compares the effects of AA to the entire range of information processing stages of human operators, such as air traffic controllers. The results provide evidence that the effectiveness of AA is dependent on the stage of task performance (human-machine system information processing) that is flexibly automated. The results suggest that humans are better able to adapt to AA when applied to lower-level sensory and psychomotor functions, such as information acquisition and action implementation, as compared to AA applied to cognitive (analysis and decision-making) tasks. The results also provide support for the use of AA, as compared to completely manual control. These results are discussed in terms of implications for AA design for aviation.Document ID20020080640Acquisition SourceLangley Research CenterDocument TypeTechnical Publication (TP)AuthorsKaber, David B.*(North Carolina State Univ. Raleigh, NC United States)*Prinzel, Lawrence J., III*(NASA Langley Research Center Hampton, VA United States)*Wright, Melanie C.*(North Carolina State Univ. Raleigh, NC United States)*Clamann, Michael P.*(North Carolina State Univ. Raleigh, NC United States)*Date AcquiredSeptember 7, 2013Publication DateSeptember 1, 2002Subject CategoryMan/System Technology And Life SupportReport/Patent NumberL-18229NASA/TP-2002-211932NAS 1.60:211932Funding Number(s)PROJECT: RTOP 711-50-21-01Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType20020080640.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Order entered July 31, 2013

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 13
- 00362
- CV
TRANSCONTINENTAL REA LTY INVESTORS, INC . , Appellant
V. SIDNEY WICKS, AS TRU STEE OF THE SIDNEY WICKS REVOCAB LE TRUST , Appellee On Appeal from t he 14th Judicial District Court

Dallas County, Texas Trial Court Cause No. DC
- 10
- 15435



### O RDER
We GRANT appellant’s July 18, 2013 opposed second motion for an extension of time to file a brief. Appellant shall file its brief on or before August 22, 2013. We caution appellant that no further extension of time will be granted absent extraordinary circumstances.

/s/ CAROLYN WRIGHT CHIEF JUSTICE
[Federal Register Volume 69, Number 189 (Thursday, September 30, 2004)]
[Notices]
[Page 58543]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-21950]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated March 29, 2004, and published in the Federal 
Register on April 29, 2004, (69 FR 23538), Lonza Riverside, 900 River 
Road, Conshohocken, Pennsylvania 19428, made application by renewal to 
the Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed 
below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma hydroxybutyric acid (2010)...........  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
------------------------------------------------------------------------

    The company plans to manufacture bulk products for the manufacture 
of finished dosage units for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Lonza Riverside to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Lonza Riverside to ensure that the company's registration 
is consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic classes of controlled substances listed.

    Dated: September 8, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-21950 Filed 9-29-04; 8:45 am]
BILLING CODE 4410-09-M
### Subpart E—Grantors and Others Treated as Substantial Owners

Sec.
671.
Trust income, deductions, and credits attributable to grantors and others as substantial owners.
672.
Definitions and rules.
673.
Reversionary interests.
674.
Power to control beneficial enjoyment.
675.
Administrative powers.
676.
Power to revoke.
677.
Income for benefit of grantor.
678.
Person other than grantor treated as substantial owner.
679.
Foreign trusts having one or more United States beneficiaries.

#### **Editorial Notes**

#### Amendments

**1976**—Pub. L. 94–455, title X, §1013(e)(1), Oct. 4, 1976, 90 Stat. 1616, added item 679.
#### § 3833.92 What happens if I do not file a transfer of interest?

Even if you record your transfer or amendment with the local recording office, BLM will not recognize the interest you acquire, or send you notice of any BLM action, decision, or contest, regarding the mining claim or site until you file the transfer with BLM (see § 1810.2 of this chapter). The Department will treat the last owner of record as the responsible party for maintaining the mining claim or site until you file a transfer notice. You cannot claim that BLM failed to give you notice of any BLM action, decision, or contest regarding a mining claim or site if you failed to file a transfer notice showing that you have an interest in the mining claim or site, before BLM took the action, made the decision, or issued a contest complaint.
Exhibit 32.1



CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





I, Joshua Ralston, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of
General Enterprise Ventures, Inc. for the quarterly period ending March 31, 2015 fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form
10-Q fairly presents in all material respects the financial condition and results of operations of General Enterprise Ventures
Inc.





|Date: April 5, 2023 |  |  | /s/ Joshua Ralston                      | 
|------------------- |  |  | --------------------------------------- | 
|                    |  |  | Joshua Ralston, Chief Financial Officer |
#### § 3427.3 Validation of information.

Any person submitting a written consent shall include with his filing a statement that the evidence submitted, to the best of his knowledge, represents a true, accurate, and complete statement of information regarding the consent for the area described.
#### Joseph Gennity, Respondent, v. City of New York, Appellant.

Carswell, Johnston, Adel, Taylor and Lewis, JJ., concur.
#### UNITED STATES of America, Plaintiff-Appellee, v. Sebastian FLORES-SERRANO, Defendant-Appellant.

No. 05-40870.

Conference Calendar.

United States Court of Appeals, Fifth Circuit.

Decided Feb. 24, 2006.

James Lee Turner, Assistant U.S. Attorney, U.S. Attorney’s Office, Southern District of Texas, Houston, TX. for PlaintiffAppellee.

Marjorie A. Meyers, Federal Public Defender, Laura Fletcher Leavitt, Assistant Federal Public Defender, Philip G. Gallagher, Federal Public Defender’s Office, Southern District of Texas, Houston, TX, for Defendant-Appellant.

Before GARZA, DENNIS, and PRADO, Circuit Judges.

PER CURIAM: *

Sebastian Flores-Serrano appeals his guilty plea conviction and sentence for possession with intent to distribute 5.14 kilograms of cocaine in violation of 21 U.S.C. § 841(a)(1) and (b)(1)(A). He contends that the provisions of § 841(a) and (b) are facially unconstitutional in light of *Apprendi v. New Jersey,*530 U.S. 466, 120 S.Ct. 2348, 147 L.Ed.2d 435 (2000). As Flores-Serrano concedes, his argument is foreclosed by circuit precedent. *See United States v. Slaughter,*238 F.3d 580, 582 (5th Cir.2000). He raises the issue only to preserve it for Supreme Court review. Accordingly, the district court’s judgment is AFFIRMED.

*

 Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT BY
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Innovate Oncology, Inc., on Form
10-QSB for the period ending September 30, 2005 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), the undersigned, Alan
Bowen, Chief Financial Officer and Principal Accounting Officer of the Company,
certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to ss. 906 of the
Sarbanes-Oxley Act of 2002, that:

(1)   The Report fully complies with the requirements of section 13 (a) or 15
      (d) of the Securities Exchange Act of 1934; and

(2)   The information contained in the Report fairly presents, in all material
      respects, the financial condition and result of operations of the Company.

Date: May 15, 2006

By: /s/ Alan Bowen
------------------------------------
Alan Bowen
CFO, Treasurer & Director
(Chief Financial Officer)

A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.
|               |  |                                                                                                                                                  
|-------------- |  | -------------------------------------------------------------------------------------------------------------------------------------------------
|EXHIBIT 32.2 - |  | CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and
accompanies the Quarterly Report on Form 10-Q/A (the Form 10-Q/A) for the quarter ended September 30, 2009 of Clear Channel Communications, Inc. (the Issuer). The undersigned hereby certifies that the Form 10-Q/A fully
complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q/A fairly presents, in all material respects, the
financial condition and results of operations of the Issuer.

Date: November 11, 2009



|       |  |                                      
|------ |  | -------------------------------------
|By:    |  | /s/ RANDALL T. MAYS                  
|Name:  |  | Randall T. Mays                      
|Title: |  | President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the
Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
# Europeiska unionens C 219I/2020

| | ISSN 1977-1061 |
| --- | --- |
| Europeiska unionens
  officiella tidning | C 219I |
| | |
| Svensk utgåva | Meddelanden och upplysningar | 63 årgången3 juli 2020 |

ISSN 1977-1061

Europeiska unionens

officiella tidning

C 219I

Svensk utgåva

Meddelanden och upplysningar

63 årgången3 juli 2020

---

| Innehållsförteckning | Sida |
| --- | --- |
| | IV   Upplysningar |
| | UPPLYSNINGAR FRÅN EUROPEISKA UNIONENS INSTITUTIONER, BYRÅER OCH ORGAN |
| | Europeiska kommissionen |
| 2020/C 219 I/01 | Tillkännagivande av upplysningar om uppskjutande av ikraftträdandet av MiFIR-förordningens bestämmelser om öppet tillträde med avseende på börshandlade derivat | 1 |

Innehållsförteckning

Sida

IV   Upplysningar

UPPLYSNINGAR FRÅN EUROPEISKA UNIONENS INSTITUTIONER, BYRÅER OCH ORGAN

Europeiska kommissionen

2020/C 219 I/01

Tillkännagivande av upplysningar om uppskjutande av ikraftträdandet av MiFIR-förordningens bestämmelser om öppet tillträde med avseende på börshandlade derivat

1

---

| SV | |
| --- | --- |

SV

---

IV Upplysningar

UPPLYSNINGAR FRÅN EUROPEISKA UNIONENS INSTITUTIONER, BYRÅER OCH ORGAN

Europeiska kommissionen

| 3.7.2020 | SV | Europeiska unionens officiella tidning | CI 219/1 |
| --- | --- | --- | --- |

3.7.2020

SV

Europeiska unionens officiella tidning

CI 219/1

---

Tillkännagivande av upplysningar om uppskjutande av ikraftträdandet av MiFIR-förordningens bestämmelser om öppet tillträde med avseende på börshandlade derivat

(2020/C 219 I/01)

I artikel 54.2 i Europaparlamentets och rådets förordning (EU) nr 600/2014 (1) (Mifir) fastställs en övergångsperiod under vilken artiklarna 35 eller 36 i Mifir inte gäller de centrala motparter eller handelsplatser som ansökt om att omfattas av detta övergångsarrangemang med avseende på börshandlade derivat.

Övergångsperioden löper ut den 3 juli 2020. I den nuvarande marknadsmiljön, med en hög grad av osäkerhet och volatilitet på grund av covid-19-pandemin, ökar de operativa riskerna för centrala motparter och handelsplatser. Ökad risk kräver större fokus på kontinuitet och bedömningen av begäranden om tillträde kan, i den nuvarande miljön, negativt påverka marknadernas korrekta funktion när det gäller handel med och clearing av börshandlade derivat. Medlagstiftarna enades därför om att förlänga övergångsperioden till och med den 3 juli 2021.

Marknadsaktörerna bör därför vara medvetna om att medlagstiftarna enades om att utvidga övergångsbestämmelserna i artikel 54.2 om artiklarna 35 eller 36 i Mifir, med verkan från och med den 4 juli 2020. Förlängningen gäller för de centrala motparter eller handelsplatser som lämnat en begäran till sina behöriga myndigheter om att dra nytta av övergångsarrangemangen när det gäller börshandlade derivat.

---

(1)  EUT L 173, 12.6.2014, s. 84.

---
**EXHIBIT32.2**

**CERTIFICATION OF VICE PRESIDENT,FINANCE**

**CALLISTO PHARMACEUTICALS, INC.**

**FORM 10-K FOR THE YEAR ENDED DECEMBER31, 2006**

**PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED**

**PURSUANTTO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I am the Vice President, Finance of CallistoPharmaceuticals, Inc., a Delaware corporation (the “Company”). I am deliveringthis certificate in connection with the Form 10-K of the Company for the yearended December 31, 2006 and filed with the Securities and Exchange Commission (“Form10-K”).

Pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certifythat, to the best of my knowledge, the Form 10-K fully complies with therequirements of Section 13(a) or Section 15(d) of the Securities Exchange Actof 1934 and that the information contained in the Form 10-K fairly presents, inall material respects, the financial condition and results of operations of theCompany.
| Date: April 17, 2007 | /s/ Bernard Denoyer |   |
|---------------------------|--------------------------|--------|
|                      | Bernard Denoyer          |
|                      | Vice President, Finance  |

 

1

----
(No. 1033

Claimant awarded $30.00.)

#### A. W. Hartman, Claimant, *vs.*State of Illinois, Respondent.

*Opinion filed May 12,*1927.

*Reimbursement*— when *award may he made.*There being no dispute as to the facts in this case, and no objection made by the State, the court enters an award in favor of claimant to reimburse him for moneys expended in the repair of his property damaged by an employee of the State.

Anna M. Moore, for claimant.

Oscar E. Carlstrom, Attorney General ; Frank R. Eagleton, Assistant Attorney General, for respondent.

Mr. Chief Justice Clarity

delivered the opinion of the court:

This is a claim for damages on account of an automobile collision between claimant and an automobile, the property and under the direction of the Dixon State Hospital.

The claim is for the sum of $30.00 for injury to claimant’s car, and, according to a letter filed by the managing officer of the Dixon Státe Hospital, the claimant should be reimbursed for the price of a new fender and labor in placing it."

Therefore the court recommends that the claimant be allowed the sum of $30.00.